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Abstract
Background: Stable simultaneous knock down of the HIV-1 coreceptors CCR5 and CXCR4 is a
promising strategy to protect cells from both R5 macrophage tropic and X4 T cell tropic as well
as dual tropic viral infections. The potency of shRNAs in targeted gene silencing qualifies them as
powerful tools for long term HIV gene therapy. Our previous work with a bispecific lentiviral
vector containing CXCR4 and CCR5 shRNAs showed efficacy in down regulating both
coreceptors and conferring viral resistance to both X4 and R5-tropic strains of HIV-1 in cultured
cell lines. To extend these results to a stem cell gene therapy setting, here we show transduction
of primary CD34+ hematopoietic progenitor cells to derive normal end stage cells that are
resistant to HIV-1 infection.
Results: The bispecific XHR lentiviral vector harboring CXCR4 and CCR5 shRNA expression
cassettes was efficient in transducing CD34+ cells. The transduced cells gave rise to
morphologically normal transgenic macrophages when cultured in cytokine media. There was a
marked down regulation of both coreceptors in the stably transduced macrophages which showed
resistance to both R5 and X4 HIV-1 strains upon in vitro challenge. Since off target effects by some
shRNAs may have adverse effects on transgenic cells, the stably transduced macrophages were
further analyzed to determine if they are phenotypically and functionally normal. FACS evaluation
showed normal levels of the characteristic surface markers CD14, CD4, MHC class II, and B7.1.
Phagocytic functions were also normal. The transgenic macrophages demonstrated normal abilities
in up-regulating the costimulatory molecule B7.1 upon LPS stimulation. Furthermore, IL-1 and
TNFα cytokine secretion in response to LPS stimulation was also normal. Thus, the transgenic
macrophages appear to be phenotypically and functionally normal.
Conclusion: These studies have demonstrated for the first time that a bispecific lentiviral vector
could be used to stably deliver shRNAs targeted to both CCR5 and CXCR4 coreceptors into
CD34+ hematopoietic progenitor cells and derive transgenic macrophages. Transgenic
macrophages with down regulated coreceptors were resistant to both R5 and X4 tropic HIV-1
infections. The differentiated cells were also phenotypically and functionally normal indicating no
adverse effects of shRNAs on lineage specific differentiation of stem cells. It is now possible to
construct gene therapeutic lentiviral vectors incorporating multiple shRNAs targeted to cellular
molecules that aid in HIV-1 infection. Use of these vectors in a stem cell setting shows great
promise for sustained HIV/AIDS gene therapy.
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Background
Gene therapy approaches using the strategy of intracellu-
lar immunization hold considerable promise towards
controlling HIV infection. Previous attempts with anti-
HIV molecules that employed RNA decoys, transdomi-
nant proteins, and ribozymes were promising towards
developing novel therapies [1-12]. With the recent discov-
ery of RNA interference (RNAi), a new and more powerful
tool has become available to add to the growing anti-HIV
arsenal. The phenomenon of RNA interference has proven
to be highly potent in post-transcriptional gene silencing
[13-15]. Mediated by sequence specific small-interfering
RNAs (siRNAs), RNAi can effectively down regulate the
expression of either viral or cellular RNA targets by selec-
tive degradation of homologous mRNAs [16]. The mech-
anism of mRNA degradation involves an endonuclease
present in the RNA-induced silencing complex (RISC)
which is guided by the antisense component of the siRNA
for target recognition [13,14]. A number of reports have
shown that delivery of siRNAs by transfection of presyn-
thesized siRNAs or plasmids encoding siRNAs into cul-
tured cells can effectively inhibit HIV-1 infections [17-26].
However, due to the transient nature of transfected
nucleic acid, the antiviral effects are only temporary. For
HIV gene therapy strategies to succeed long range, it is
necessary that siRNA coding transgenes be maintained
and expressed long term in a virus susceptible target cell.
In this regard, lentiviral vectors have proven to be highly
effective in high efficiency gene transduction and sus-
tained gene expression [27-32].
A number of studies using siRNAs have targeted HIV genes
as well as the cellular molecules critical for HIV entry,
namely CD4, CXCR4 and CCR5 [18,19,21,23,24,33-37].
SiRNAs targeting HIV genes alone will not be sufficient to
ward off chronic infection due to the high possibility of
generating escape mutants [38,39]. Therefore by targeting
host cellular genes critical for viral entry and/or replica-
tion, a more sustained efficacy of antiviral effects may be
obtained. As a critical player in immunological function,
CD4 is physiologically indispensable. The chemokine
receptors CXCR4 and CCR5 also play critical roles as core-
ceptors for viral entry during infection with T cell tropic
X4 and macrophage tropic R5 HIV-1 viral strains respec-
tively [40,41]. Their sustained knock down may prove to
be more efficacious for long range siRNA therapy.
Since both R5 and X4-tropic viral strains are involved in
disease pathogenesis, it is important to consider both
coreceptors when developing effective therapeutics. In a
segment of the human population, a naturally occurring
32-bp deletion in the CCR5 gene results in the loss of
coreceptor function thus conferring significant resistance
to HIV infection [42-44]. Homozygous or heterozygous
individuals with this mutation remain physiologically
normal. With regard to the CXCR4 coreceptor, it was
found to be dispensable for T cell development and mat-
uration in murine studies [45].
Based on this rationale, recent work with synthetic siRNAs
demonstrated that down regulating either CXCR4 or
CCR5 will protect cells from X4 or R5 HIV-1 strains,
respectively, at the level of viral entry [18,19,21,23,24,33-
37]. Stable expression of an anti-CCR5 siRNA was also
achieved using a lentiviral vector. However, down regulat-
ing CCR5 alone in the face of an HIV-1 infection is insuf-
ficient [34]. Therefore, we recently demonstrated that
synthetic bispecific combinatorial constructs as well as a
bispecific lentiviral vector targeting both CXCR4 and
CCR5 showed efficacy in inhibiting HIV-1 infections in
cell culture lines [24,37]. In translating these findings into
a stem cell gene therapy setting, this bispecific lentiviral
vector was used in the present studies to generate shRNA
expressing transgenic macrophages.
Macrophages, along with T cells, are major cell targets of
HIV infections. Programming these cells to express shR-
NAs targeted to the essential coreceptors, CXCR4 and
CCR5, could confer resistance to HIV infection. Macro-
phages also have a significant role in immune system
functions as antigen presenting cells and as major effector
cells in inflammation. Therefore, protecting macrophages
from HIV infection is important in maintaining immune
system homeostasis. Since shRNAs can have possible off
target effects thus dysregulating cellular physiology, trans-
genic macrophages also need to be assessed for proper
functionality [46]. Here we show that CD34+ hematopoi-
etic progenitor cell derived macrophages expressing shR-
NAs targeting CXCR4 and CCR5 are functionally normal
and resist infection to both X4 and R5-tropic strains of
HIV-1.
Results
Lentiviral vector transduction of CD34+ cells with CXCR4 
and CCR5 shRNAs and derivation of mature macrophages
A bispecific lentiviral vector XHR, coding for an shRNA
targeting CXCR4 driven by a U6 promoter and a CCR5
shRNA under the control of an H1 promoter was designed
as previously described (Fig. 1) [37]. This vector also con-
tains an EGFP reporter gene downstream from the shRNA
cassettes. CD34+ hematopoietic progenitor cells were
transduced with either control GFP or XHR vectors. Cells
were then sorted for EGFP and driven towards a myeloid
lineage in semi-solid methyl cellulose cytokine media to
generate transgenic macrophages. No significant differ-
ences were found in the levels of macrophages obtained
when compared between the control GFP vector and XHR
vector transduced cells or control non-transduced CD34+
cells. The morphology of the transgenic macrophages also
appeared normal (data not shown).Retrovirology 2005, 2:53 http://www.retrovirology.com/content/2/1/53
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Down regulation of HIV-1 coreceptors CXCR4 and CCR5 
in transgenic macrophages
CD34+ derived macrophages normally express both
major HIV-1 coreceptors, CXCR4 and CCR5, albeit a
lower level of CXCR4. In XHR transduced cells FACS anal-
ysis showed an 82% decrease in CXCR4 expression. GFP-
alone control vector transduced cells and non-transduced
cells displayed normal levels of CXCR4 expression (94%)
(Fig. 2A). Similar analysis for CCR5 expression showed a
73% decrease in XHR transduced macrophages with nor-
mal levels seen in GFP-alone vector transduced cells simi-
lar to non-transduced cells (98%) (Fig. 2B). Thus, stably
transduced macrophages exhibited significant down regu-
lation of both the coreceptors CXCR4 and CCR5 due to
shRNA targeting.
XHR transgenic macrophages resist HIV-1 challenge
To determine if down regulation of CXCR4 and CCR5
coreceptors conferred viral resistance, transduced macro-
phages were challenged with X4-tropic (NL4-3) and R5-
tropic (BaL-1) strains of HIV-1. Antigen ELISAs to detect
viral p24 in culture supernatants were performed on vari-
ous days post-infection. Over a 2-log reduction in viral
yield was seen in XHR transduced macrophages chal-
lenged with X4-tropic HIV-1 as compared to control cells
(Fig. 3A). In BaL-1 challenge experiments, there was over
a 1-log reduction in viral titer in XHR transduced macro-
phages compared to control cells (Fig. 3B). Thus stable
coreceptor down regulation by siRNAs resulted in marked
protection of transgenic macrophages against viral
challenge.
Transgenic macrophages display characteristic phenotypic 
cell surface markers
Macrophages are critical players in the immune system
and also participate in the inflammatory response. Recent
Bispecific lentiviral vector (XHR) encoding anti-CXCR4 and CCR5 shRNAs Figure 1
Bispecific lentiviral vector (XHR) encoding anti-CXCR4 and CCR5 shRNAs: A) Control transfer vector pHIV-7-GFP 
encoding a CMV promoter driven EGFP reporter gene. B) To derive the bispecific vector pHIV-XHR-GFP, a U6 promoter 
driven short hairpin CXCR4 shRNA cassette was cloned into the BamHI site upstream of the CMV-EGFP cassette. The H1-
CCR5 shRNA cassette was inserted into an MluI site downstream to the U6-CXCR4 shRNA cassette.Retrovirology 2005, 2:53 http://www.retrovirology.com/content/2/1/53
Page 4 of 11
(page number not for citation purposes)
work demonstrated possible off target effects of some siR-
NAs [46]. Such effects may disrupt the phenotypic
properties of macrophages or alternatively, may interfere
with their normal function. Therefore, transgenic macro-
phages were subjected to phenotypic analyses to assess
their characteristic cell surface markers by FACS. Levels of
the monocyte/macrophage marker CD14 in XHR macro-
phages were found to be similar to GFP-alone transduced
or nontransduced cells (98% and 97% respectively) (Fig.
4A). Similarly the levels of CD4, a primary HIV-1 receptor,
were found at comparable levels for XHR and GFP-alone
transduced macrophages at 95% and 93% respectively,
coinciding with levels in nontransduced cells (Fig. 4B).
The antigen presenting cell surface specific marker, HLA-
Down regulation of the coreceptors CXCR4 and CCR5 in XHR transgenic macrophages Figure 2
Down regulation of the coreceptors CXCR4 and CCR5 in XHR transgenic macrophages: GFP-alone and XHR 
transduced CD34+ derived macrophages were labeled with PE-CY5 conjugated antibodies specific for CXCR4 (A) and CCR5 
(B) and analyzed by FACS. Control, nontransduced macrophages are shown superimposed as unshaded areas.Retrovirology 2005, 2:53 http://www.retrovirology.com/content/2/1/53
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DR (MHC II) present on macrophages is critical for pre-
senting antigen to CD4+ T cells. A second co-stimulatory
molecule B7.1 needed to activate T cells is present at low
levels on normal macrophages. Its expression is elevated
upon activation with certain stimuli such as LPS. Our eval-
uation showed that XHR transgenic macrophages dis-
played similar levels of HLA-DR (92%) when compared
to GFP-alone (89%) or with non transduced macrophages
(Fig. 4C). The levels of the costimulatory molecule B7.1
were found to be normal at ~15% without stimulation.
The transgenic macrophages also displayed capacity to
upregulate B7.1 (65%) after LPS stimulation similar to
that seen with vector alone and non-transduced control
cells (Fig. 4D).
Transgenic macrophages are functionally normal
As stable expression of some shRNAs could have possible
off-target global effects leading to disruption of normal
cellular functions, we performed functional assays on
transgenic macrophages to evaluate this possibilty. A typ-
ical function of macrophages is phagocytosis of foreign
material and presentation of antigenic peptides. To deter-
mine if XHR transgenic macrophages retained the phago-
cytic function, they were presented with fluorescently
labeled  E. coli (Bioparticles®). Foreign cell uptake was
measured by FACS. In comparing non-transduced, GFP-
alone transduced, and XHR transduced macrophages, no
significant differences in the phagocytic capacity were
found between the transgenic macrophages and the vector
alone transduced or non-transduced cells. Based on flu-
orecscence levels, XHR macrophage phagocytosis was
quantified at 68.2% (Fig. 5E) compared to non trans-
duced and GFP-alone cells at 63.5% and 61.5%, respec-
tively (Fig. 5C and 5D). Transduced Magi-CXCR4 cells,
serving as non-phagocytic cell controls did not display
any phagocytic activity (Fig. 5B).
Due to their role in immunity and inflammatory
response, macrophages secrete and respond to a number
of important cytokines that include IL-1 and TNF-α. To
determine if siRNA transgenic macrophages retained their
functional capacity to secrete these cytokines at normal
levels, they were stimulated with LPS. Levels of released
cytokines were measured by ELISA. No significant differ-
ences were seen in levels of IL-1 and TNF-α cytokine secre-
tion among the transgenic and control cell types (Fig. 6A
and 6B). Basal levels of cytokine production were also
detected without LPS stimulation with no differences seen
between cell types (data not shown). Collectively the
above data showed that coreceptor siRNA transgenic mac-
rophages were phenotypically and functionally normal.
Discussion
Down regulation of the major HIV-1 coreceptors CXCR4
and CCR5 in virus susceptible cells is a promising
approach to prevent viral entry and establishment of
HIV-1 resistance of XHR transgenic macrophages Figure 3
HIV-1 resistance of XHR transgenic macrophages: Control nontransduced (◆ ), GFP-alone (■ ), and XHR (▲ ) trans-
duced CD34+ derived macrophages were challenged with (A) X4-tropic NL4-3 and (B) R5-tropic BaL-1 strains of HIV-1. p24 
ELISAs were performed on culture supernatants taken at various time points post-infection. Experiments were performed in 
triplicate.Retrovirology 2005, 2:53 http://www.retrovirology.com/content/2/1/53
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productive infection. As noted above, targeting both core-
ceptors simultaneously will have the added advantage of
protecting cells from both X4 and R5 tropic viruses as well
as dual tropic strains. In the present studies we have
shown that a bispecific lentiviral vector was effective in
transducing the respective siRNAs targeted to these core-
ceptors into primary CD34+ hematopoietic progenitor
cells which can give rise to all the blood cell lineages
including macrophages, T cells, and dendritic cells.
Since siRNAs are new tools being used for genetic manip-
ulation, it is necessary that they be systematically evalu-
ated in a stem cell setting for their long range utility in
protecting end stage differentiated cells such as macro-
phages. Recent studies have demonstrated that some
siRNA constructs may have off target effects [46]. This may
adversely affect cell differentiation pathways. Our results
have demonstrated that mature macrophages could be
derived from lentivirally transduced shRNAs targeting
both CXCR4 and CCR5. No significant differences were
found in the yields of macrophages from control non-
transduced, control GFP-alone vector, and the bispecific
shRNA vector transduced CD34+ cells when cultured in
cytokine media permitting cell differentiation. This sug-
gests that the respective shRNAs did not interfere with the
lineage specific differentiation of gene transduced CD34+
cells into macrophages.
The transgenic macrophages showed significant down
regulation of the respective targeted coreceptors CXCR4
and CCR5. Thus, differentiated cells retained functional
shRNAs that were effective against their respective target
mRNAs. When challenged with HIV-1 in vitro they showed
marked resistance to infection with both X4 and R5 tropic
Transgenic macrophages display normal cell surface markers Figure 4
Transgenic macrophages display normal cell surface markers: GFP-alone and XHR transduced CD34+ derived mac-
rophages were labeled with antibodies specific for (A) CD14, (B) CD4, and (C) HLA-DR and analyzed by FACS. Control, non-
transduced macrophages are shown superimposed as unshaded areas. (D) B7.1 upregulation of transgenic macrophages 
stimulated with LPS. Twenty-four hours post-stimulation, macrophages were labeled with a PE-CY5 conjugated anti-B7.1 anti-
body and analyzed by FACS. B7.1 upregulation data are representative of triplicate experiments.Retrovirology 2005, 2:53 http://www.retrovirology.com/content/2/1/53
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viral strains. Most primary infections with HIV-1 are
believed to be caused by R5 tropic HIV-1 as it is transmit-
ted with relative ease with macrophages as the initial in
vivo target. During disease progression, X4 tropic viruses
are believed to emerge. However recent studies showed
that primary X4 HIV-1 isolates could also infect macro-
phages obtained from human tissue establishing that ini-
tial infection of these cells in vivo is not confined to R5
strains [51]. Therefore, protecting macrophages against
both R5 and X4 tropic viruses is essential to prevent initial
viral infection. Thus, the bispecific lentiviral vector har-
boring both CXCR4 and CCR5 shRNAs, described here,
would be ideal in preventing HIV-1 infection at the cell
entry stage.
Phagocytosis of fluorescently labeled E.coli by CD34+ derived macrophages Figure 5
Phagocytosis of fluorescently labeled E.coli by CD34+ derived macrophages: E. coli Bioparticles® were added 
directly to the cultured macrophages along with 5 µg/ml LPS. Twenty four hours post-stimulation, cells were analyzed by 
FACS. (A) Control macrophages without Bioparticles®. Panels B-E show plots of cells incubated with Bioparticles® (B) Trans-
duced Magi-CXCR4 (non-phagocytic cell culture), (C) nontransduced, (D) GFP-alone, and (E) XHR macrophages. These data 
are representative of triplicate experiments.
XHR transgenic macrophages secrete normal levels of the cytokines IL-1 and TNFα Figure 6
XHR transgenic macrophages secrete normal levels of the cytokines IL-1 and TNFα: Control nontransduced, 
GFP-alone, and XHR macrophages were stimulated with 5 µg/ml LPS. On days 1, 2, and 3 post-stimulation, supernatants were 
collected and assayed by ELISA for cytokine secretion of (A) IL-1 and (B) TNFα. Experiments were done in triplicate.Retrovirology 2005, 2:53 http://www.retrovirology.com/content/2/1/53
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A requirement for successful HIV-1 gene therapy is for
transgenic virus resistant cells to be phenotypically and
functionally normal to maintain and restore the body's
immunological function. Accordingly, transgenic macro-
phages were evaluated to determine if they met these cri-
teria. Although the levels of coreceptor expression
diminished substantially as a result of shRNA targeting,
phenotypic analyses of shRNA transgenic macrophages
showed that they were otherwise phenotypically normal.
This was shown by the comparable levels of CD14 and
CD4 cell surface markers for both control cells and shRNA
transgenic macrophages. Levels of the MHC class II mole-
cule HLA-DR were also found to be normal. Upregulation
of the costimulatory molecule B7.1 in response to LPS
stimulation was comparable between shRNA transgenic
and control vector containing cells. Furthermore, phago-
cytic functions were also found to be normal. To analyze
the critical function of macrophages in secreting cytokines
during the inflammatory response, the levels of IL-1 and
TNF-α secretion were analyzed. Our results demonstrated
that the expression of CXCR4 and CCR5 shRNAs and the
subsequent downregulation of these chemokine receptors
had no apparent effect on IL-1 or TNF-α secretion. These
data collectively suggest that phenotypically and function-
ally normal macrophages could be obtained from CD34+
cells lentivirally transduced with CXCR4 and CCR5
shRNA constructs. These results establish for the first time
that simultaneous knock down of both the chemokine
receptors CXCR4 and CCR5 have no apparent adverse
effects on macrophage differentiation, phenotype or
function.
The above data showed the efficacy of this bispecific
shRNA construct in deriving HIV-1 resistant macrophages
in vitro in a stem cell setting. Further preclinical testing of
this construct is needed in vivo to determine its suitability
for use in the human. The SCID-hu mouse model that
harbors a functional human thymus permits evaluation of
vector transduced CD34+ cells to determine their capacity
to give rise to mature T cells. The transgenic T lymphocytes
so derived could be assessed for their functionality and
viral resistance as we have shown previously [29]. Adverse
effects are not expected by the stable knock down of CCR5
in vivo as it was previously documented in many studies
that individuals harboring a 32 bp deletion in the CCR5
gene do not exhibit any immunological abnormalities
[42-44]. However, stable CXCR4 knock down may have
possible side effects in a stem cell setting due to its role in
cell homing [52]. Therefore, a systematic evaluation of the
CCR5 and CXCR4 bispecific construct in vivo in the SCID-
hu mouse model is necessary to determine its efficacy and
possible toxicity in differentiated T cells prior to its evalu-
ation in human subjects. Such studies are currently
underway.
Conclusion
Stable simultaneous knock down of both the coreceptors
CCR5 and CXCR4 is necessary to prevent HIV-1 infection
at the entry level by both R5 and X4, as well as dual tropic
viral strains. Our present studies have demonstrated for
the first time that a bispecific lentiviral vector could be
used to stably deliver shRNAs targeted to both CCR5 and
CXCR4 coreceptors into CD34+ hematopoietic progeni-
tor cells and derive transgenic macrophages. Stable down
regulation of both the coreceptors was achieved in trans-
genic macrophages which displayed marked resistance to
HIV-1 challenge in vitro. The siRNA expressing macro-
phages were also found to be phenotypically and func-
tionally normal. It is now possible to construct gene
therapeutic lentiviral vectors incorporating multiple siR-
NAs targeted to cellular molecules that aid in HIV-1 infec-
tion. Use of these vectors in a stem cell setting shows great
promise for sustained HIV/AIDS gene therapy.
Methods
Generation of CXCR4 and CCR5 bispecific siRNA lentiviral 
vector XHR
A third-generation lentiviral vector system was used to
produce the bispecific shRNA-expressing lentiviral vector
[47]. The transfer vector pHIV-7-GFP was designed to con-
tain an anti-CXCR4 shRNA cassette under the control of
the Pol-III U6 promoter and an anti-CCR5 shRNA cassette
under the control of the Pol-III H1 promoter, as previ-
ously described [37]. The anti-CXCR4 shRNA targets the
CXCR4 transcript at nucleotides 3–23 and the anti-CCR5
shRNA targets the CCR5 transcript at nucleotides 13–31.
A depiction of this bispecific lentiviral vector along with
two important cis-acting elements is shown (Fig. 1). The
two  cis-acting elements, namely, the central DNA flap
consisting of the cPPT and CTS (to facilitate the nuclear
import of the viral preintegration complex) and the WPRE
(to promote nuclear export of transcripts and/or increase
the efficiency of polyadenylation of transcripts), are used
to enhance the performance of the vector [47,48]. To gen-
erate lentiviral vectors, 293T cells, maintained in
complete DMEM containing 10% FBS, were transfected
with the plasmids pCHGP-2, pCMV-Rev, pCMV-VSVG,
and the appropriate transfer vector, GFP-alone or XHR,
using a calcium phosphate transfection kit (Sigma-
Aldrich, St. Louis, MO). Cell culture supernatants were
collected at 24, 36, 48, and 60 hours post-transfection,
pooled, and concentrated by ultracentrifugation. Vector
titers were then analyzed on 293T cells by FACS for EGFP
expression. Concentrated vector titers ranged from 8.0 ×
107  to 1.5 × 108  for XHR and GFP-alone vectors,
respectively.Retrovirology 2005, 2:53 http://www.retrovirology.com/content/2/1/53
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Transduction of CD34+ hematopoietic stem cells and 
derivation of macrophages
CD34+ hematopoietic progenitor cells were purified from
human fetal liver by selection with monoclonal antibody-
conjugated immunomagnetic beads (Miltenyi Biotech,
Auburn, CA)[8]. The purity of CD34+ cells was deter-
mined by FACS using a PE conjugated CD34+ antibody.
The purity of cells was routinely >93% (data not shown).
CD34+ cells were maintained in Iscove's modified Dul-
becco's growth medium containing IL-3, IL-6, and stem
cell factor (SCF) each at 10 ng/ml (R&D Systems, Minne-
apolis, MN) supplemented with 10% FBS. Lentiviral vec-
tor transductions were performed on 2 consecutive days at
an m.o.i. of 30 in the presence of polybrene (4 ug/ml).
Transduced cells were then sorted by FACS for EGFP
expression and subsequently placed in semi-solid methyl-
cellulose Methocult media (Stem Cell Technologies, Van-
couver, BC, Canada) for 10–12 days to derive myeloid
colonies. Total myeloid colonies were then pooled and
cultured  in vitro in DMEM supplemented with the
cytokines M-CSF (25 ng/ml) and GM-CSF (25 ng/ml)
(R&D Systems, Minneapolis, MN) for 4 days to derive
mature macrophages.
Phenotypic and functional analysis of transgenic 
macrophages
To determine if stem cell derived anti-coreceptor shRNA
transgenic macrophages were otherwise phenotypically
normal, analysis of macrophage cell surface markers was
performed by FACS with respective conjugated antibod-
ies, PE-CD14 (Caltag, Burlingame, CA), PE-HLA-DR, PE-
CY5-CD4, PE-CY5-CXCR4, and PE-CY5-CCR5 (BD Bio-
sciences, San Jose, CA).
Activated macrophages up-regulate the expression of B7.1
co-stimulatory molecules upon stimulation with various
stimuli. Accordingly, control non-transduced, GFP-alone,
and XHR vector transduced macrophages were stimulated
with LPS (5 µg/ml) (Sigma-Aldrich, St. Louis, MO).
Twenty-four hours post-stimulation, macrophages were
stained with PE-CY5 conjugated anti-B7.1 antibody (BD
Biosciences, San Jose, CA) and analyzed by FACS. FACS
analyses were performed on the Beckman Coulter Epics
XL using ADC software for analysis.
Macrophages play an important role in the immune sys-
tem as phagocytes. To determine if XHR transgenic mac-
rophages retained the ability to phagocytose foreign
material, a phagocytosis assay utilizing tetramethylrhod-
amine fluorescently labeled E. coli Bioparticles® (Invitro-
gen, Carlsbad, CA) were used. To the cell culture media, 5
ug/ml of LPS and 5 ug/ml of E. coli particles were added.
Twenty-four hours post-addition, cells were analyzed by
FACS. Transduced Magi-CXCR4, maintained as previously
described [49,50], were used as a non-phagocytic cell con-
trol. Bioparticles® were detected in the PE (FL2) channel
for FACS analysis.
Transgenic macrophages were also analyzed for the secre-
tion of two major cytokines, IL-1 and TNF-a. Macrophages
were stimulated with 5 ug/ml of LPS. On days 1, 2, and 3
post-stimulation, cell culture supernatant samples were
collected and analyzed by a Quantikine® ELISA kit (R&D
Systems, Minneapolis, MN). Non-stimulated superna-
tants were also analyzed for basal levels of cytokine
secretion.
HIV-1 Challenge of CXCR4 and CCR5 siRNA Transgenic 
Macrophages
To determine if the stable down regulation of CXCR4 and
CCR5 conferred resistance to HIV-1 infection in CD34+
derived macrophages, cells were challenged with X4
(NL4-3) or R5 (BaL-1) tropic strains of HIV-1. Both NL4-
3 and BaL-1 challenge experiments were carried out at an
m.o.i. of 0.01 for 2 hours in the presence of polybrene (4
ug/ml). Viral supernatants were collected on various days
post-infection for p24 antigen ELISAs. To quantify viral
p24 levels, a Coulter-p24 kit (Beckman Coulter, Fullerton,
CA) was used.
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